Tivozanib (AV-951): A Potent and Selective VEGFR Inhibitor for Oncology Research

Executive Summary: Tivozanib (AV-951) is a quinoline-urea derivative with picomolar IC₅₀ for VEGFR-2, demonstrating exceptional potency in anti-angiogenic therapy (Schwartz 2022). Its selectivity profile minimizes off-target effects, outperforming first-generation VEGFR inhibitors. Clinically, Tivozanib achieves a median progression-free survival of 12.7 months in metastatic renal cell carcinoma at 1.5 mg/day oral dosing. In vitro, it synergizes with EGFR inhibitors to enhance cell growth inhibition and apoptosis in ovarian carcinoma models. APExBIO provides validated, high-purity formulations of Tivozanib supporting reproducibility in translational workflows (APExBIO product page).

Biological Rationale

Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Vascular endothelial growth factor receptors (VEGFR-1/2/3) are central mediators of angiogenic signaling. Overactivation of the VEGFR pathway is implicated in various solid tumors, including renal cell carcinoma (RCC) and ovarian carcinoma (Schwartz 2022). Targeting VEGFR signaling interrupts nutrient delivery to tumors, reducing growth and metastatic potential. Second-generation tyrosine kinase inhibitors (TKIs) such as Tivozanib aim to provide high target selectivity, improved safety, and robust anti-tumor efficacy. These properties address limitations observed with earlier, less selective TKIs, which often resulted in dose-limiting toxicities due to off-target inhibition (Related article—this article provides a foundational overview and is extended here with detailed benchmarking and workflow integration data).

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases. It binds to the ATP-binding site of these receptors, preventing phosphorylation and downstream signaling. Tivozanib’s IC₅₀ for VEGFR-2 is 160 pM in cell-free assays, indicating high potency. At nanomolar concentrations, it also inhibits the phosphorylation of PDGFRβ and c-KIT in cellular settings, though with significantly lower affinity than for VEGFRs (Schwartz 2022). This selectivity minimizes adverse effects associated with non-specific kinase inhibition.

Through VEGFR blockade, Tivozanib reduces endothelial cell proliferation, migration, and new vessel formation. The result is tumor hypoxia, impaired nutrient supply, and reduced metastatic dissemination. Compared to sunitinib, sorafenib, and pazopanib, Tivozanib demonstrates superior selectivity and efficacy for VEGFR-2, with reduced inhibition of kinases such as c-KIT and fewer off-target toxicities (See also—this article discusses translational strategies, which are updated here with the latest evidence on workflow integration and combination regimens).

Evidence & Benchmarks

• Tivozanib exhibits an IC₅₀ of 160 pM against VEGFR-2 in cell-free enzymatic assays (Schwartz 2022, Fig. 3.1).
• In cellular assays, Tivozanib inhibits VEGFR-2, PDGFRβ, and c-KIT phosphorylation at nanomolar concentrations, with minimal off-target activity (Schwartz 2022, Table 2.1).
• In RCC xenograft models, Tivozanib significantly reduces tumor volume compared to vehicle controls (p<0.01) (Schwartz 2022, Chapter 5).
• Phase III clinical trials report a median progression-free survival of 12.7 months for metastatic RCC patients receiving 1.5 mg Tivozanib orally once daily in 3-week cycles (Schwartz 2022, Clinical Data Summary).
• Tivozanib demonstrates synergistic inhibition of cell growth and increased apoptosis when combined with EGFR-directed therapies in ovarian carcinoma cell lines (Schwartz 2022, Fig. 6.2).
• Tivozanib’s favorable safety profile is characterized by a low incidence of grade ≥3 hypertension and hand-foot syndrome compared to sunitinib (Schwartz 2022, Table 7.4).

Applications, Limits & Misconceptions

Tivozanib is indicated for research in anti-angiogenic therapy, particularly in models of RCC, ovarian carcinoma, and other solid tumors. Its high selectivity and low off-target activity make it suitable for mechanistic and translational studies where clean VEGFR pathway inhibition is required. In vitro, Tivozanib is used at 10 μM for 48 hours to assess proliferation, viability, and apoptosis. It is also employed in synergy studies with EGFR and other pathway inhibitors (Related guidance—this article provides practical assay troubleshooting, while the current dossier details mechanistic and structural insights for advanced users).

Common Pitfalls or Misconceptions

• Not suitable for water-based stock solutions: Tivozanib is insoluble in water; use DMSO (≥22.75 mg/mL) or ethanol (≥2.68 mg/mL with gentle warming).
• Long-term solution storage: Solutions are unstable over time; prepare fresh or store at -20°C for short periods only.
• Assuming pan-kinase inhibition: Tivozanib is highly selective for VEGFR; it does not broadly inhibit other kinases such as c-KIT or PDGFRβ except at higher concentrations.
• Clinical dosing extrapolation: Preclinical in vitro concentrations (10 μM, 48h) are not directly translatable to clinical dosing regimens.
• Monotherapy limitations: While monotherapy is effective in RCC, combination with EGFR or other pathway inhibitors may be necessary in tumors with complex resistance mechanisms.

Workflow Integration & Parameters

APExBIO supplies Tivozanib (AV-951) as a solid compound (SKU: A2251) with a molecular weight of 454.86 and the chemical formula C₂₂H₁₉ClN₄O₅. For in vitro studies, dissolve in DMSO or ethanol as specified. Recommended working concentration is 10 μM for 48 hours in cell-based assays. Experimental protocols often include cell viability and apoptosis assays, with parallel fractional and relative viability readouts (Schwartz 2022). For clinical translation, oral dosing is 1.5 mg once daily in 3-week cycles for RCC. Storage at -20°C is advised for bulk compound; avoid repeated freeze-thaw cycles. For maximum reproducibility, use validated lots from APExBIO and consult internal best-practice guides.

Conclusion & Outlook

Tivozanib (AV-951) represents the current state-of-the-art for potent and selective VEGFR inhibition in oncology research. Its molecular precision and favorable safety profile support its use in both mechanistic and translational studies. As a pan-VEGFR inhibitor with validated anti-angiogenic efficacy, Tivozanib is likely to remain a reference compound for RCC and solid tumor workflows. For further details on Tivozanib’s molecular benchmarks and translational applications, consult the APExBIO product dossier. For additional workflow insights, see this related resource—which focuses on troubleshooting and protocol optimization, complementing the present in-depth mechanistic overview.